Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667420 · ClinicalTrials.gov registry record · Phase 1
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00667420: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00667420 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667420, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
Interventions
- DRUG panitumumab, epirubicin, oxaliplatin, xeloda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667420
The ClinicalTrials.gov registry entry for NCT00667420 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which panitumumab, epirubicin, oxaliplatin, xeloda is the first listed.
NCT00667420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667420 about?
NCT00667420 is a clinical study titled "Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma". A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
What is the current status of trial NCT00667420?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00667420?
The interventions under investigation include: panitumumab, epirubicin, oxaliplatin, xeloda (DRUG).
Who is sponsoring clinical trial NCT00667420?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.